Navigation Links
Pacira Pharmaceuticals, Inc. Announces Phase 3 EXPAREL™ Data Presentation at the American Society of Colon and Rectal Surgeons 2011 Annual Meeting
Date:5/16/2011

>

Pacira Pharmaceuticals, Inc. is an emerging specialty pharmaceutical company focused on the development, manufacture and commercialization of novel pharmaceutical products, based on its proprietary DepoFoam drug delivery technology, for use in hospitals and ambulatory surgery centers. In December 2010, Pacira announced that its New Drug Application (NDA) for EXPAREL, the company's most advanced investigational product candidate, had been accepted for filing by the U.S. Food and Drug Administration (FDA). The FDA has assigned a Prescription Drug User Fee Act (PDUFA) goal date of July 28, 2011 for the review of the EXPAREL NDA. EXPAREL is a bupivacaine-based product and has completed extensive Phase 3 clinical development for postoperative analgesia by infiltration. EXPAREL consists of bupivacaine encapsulated in DepoFoam, which is designed to address the limitations of widely used medications by enhancing their dosing and/or administration profile. Additional information about Pacira is available at www.pacira.com.

About EXPAREL™

EXPAREL is Pacira's proprietary drug candidate consisting of bupivacaine encapsulated in DepoFoam®, both of which are currently used separately in FDA-approved products. Bupivacaine is a well-characterized anesthetic/analgesic that has an established safety profile with more than 20 years of use in the United States. Market data indicate that there is an unmet medical need for a longer-acting anesthetic/analgesic for postsurgical pain management. Several Phase 2 and Phase 3 clinical trials have been completed for EXPAREL and suggest statistically significant reduction of pain in soft tissue and orthopedic surgery in different surgical models. Clinical data from Phase 3 trial 316 suggests that EXPAREL provides analgesia for up to 72 hours post-surgery, the primary endpoint for the trial. The safety of EXPAREL was evaluated in 10 randomized, double-blind, local adm
'/>"/>

SOURCE Pacira Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Pacira Pharmaceuticals, Inc. Reports First Quarter 2011 Financial Results
2. Pacira Pharmaceuticals, Inc. Announces EXPAREL™ Data Presentations
3. Pacira Pharmaceuticals, Inc. Announces Timing for First Quarter 2011 Financial Results Webcast and Conference Call
4. Pacira Pharmaceuticals to Present at BioCentury Future Leaders in the Biotech Industry Conference
5. Pacira Pharmaceuticals Reports Fourth Quarter and 2010 Financial Results
6. Pacira Pharmaceuticals to Present at the Barclays Capital 2011 Global Healthcare Conference
7. Pacira Pharmaceuticals EXPAREL™ Data to be Featured at 2011 ASCPT 112th Annual Meeting
8. Pacira Pharmaceuticals Highlights Additional Safety Data on EXPAREL™ for Postsurgical Pain Relief at 2011 American Academy of Orthopaedic Surgeons Annual Meeting
9. Pacira Pharmaceuticals, Inc. Announces Pricing of Its Initial Public Offering
10. Pacira Pharmaceuticals Presents New Data from EXPAREL Phase 3 Study at Orthopaedic Research Societys 57th Annual Meeting
11. Pacira Pharmaceuticals Announces FDA Acceptance of EXPAREL™ New Drug Application for Pain Management
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... Denmark and ATLANTA , August ... the US Food and Drug Administration (FDA) cleared the MagVita ... in adult patients who have failed to receive satisfactory improvement ... a non-invasive technique for stimulating neural tissue in the part ... Disorder. The procedure has been proven safe and effective and ...
(Date:8/28/2015)... LONDON , August 28, 2015 ... approach seamlessly connects people, technologies and care ... improving outcomes and the cost of healthcare delivery ... AEX: PHIA) today announced its presence at  ESC Congress 2015 , ... Heart Model A.I. , EchoNavigator and IntelliSpace Cardiovascular, that connect ...
(Date:8/27/2015)... -- Biosimilars are not generics and the Biologics ... Drug Administration (FDA) for recognizing that each biosimilar ... issued today. The FDA,s draft guidance on nonproprietary ... for biological products to bear a nonproprietary name ... the agency,s thinking that "there is a need ...
Breaking Medicine Technology:Therapy System for Treating Major Depressive Disorder Receives FDA Clearance 2Therapy System for Treating Major Depressive Disorder Receives FDA Clearance 3Philips Showcases New Integrated Cardiology Solutions to Advance Minimally Invasive Procedures at ESC Congress 2015 2Philips Showcases New Integrated Cardiology Solutions to Advance Minimally Invasive Procedures at ESC Congress 2015 3Philips Showcases New Integrated Cardiology Solutions to Advance Minimally Invasive Procedures at ESC Congress 2015 4Biologics Prescribers Collaborative (BPC) Statement on FDA Draft Guidance entitled "Nonproprietary Naming of Biological Products" 2
... Ontario, July 18, 2011 CardioGenics Holdings Inc. (CGNH.OB) ... available for on-demand viewing at the RetailInvestorConferences website. ... will be available 24/7 for 90 days. Investors may ... the next three weeks. About CardioGenics ...
... July 18, 2011 Coronado Biosciences, Inc. (the "Company"), ... immunotherapy agents for the treatment of autoimmune diseases and ... on Form 10 with the Securities and Exchange Commission ... the purpose of becoming a reporting company.  The filing ...
Cached Medicine Technology:CardioGenics Holdings Inc. Presentation Now Available for On-Demand Viewing at RetailInvestorConferences.com 2Coronado Biosciences Files to Become a Public Reporting Company 2
(Date:8/29/2015)... Raleigh, NC (PRWEB) , ... August 29, 2015 ... ... about how mesothelioma develops, may extend and improve the lives of patients, according ... its website. Click here to read the full article. , The ...
(Date:8/29/2015)... ... August 29, 2015 , ... Brands like Toppik , ... standard shipping costs. , “Before, a threshold of $49.00 was required to qualify for ... items qualify for free standard shipping for customers regardless of the item’s selling price.” ...
(Date:8/29/2015)... ... 29, 2015 , ... ProDrop Particles includes over 40 particle backdrops designed for ... unique footage that users can shrink and stretch in the Final Cut Pro X ... customize color, brightness, scale, speed, range, and flare attributes with intuitive controls found in ...
(Date:8/29/2015)... ... August 29, 2015 , ... Hamstring strain ... stretching, soft tissue manipulation. Platelet rich plasma injections also have mixed results. ... improve treatment outcomes. This localized treatment seems to address the symptoms and ...
(Date:8/29/2015)... TX (PRWEB) , ... August 29, 2015 , ... ... allows the company to freely market and sell Arterosil and Arterosil HP, and ... Health Sciences, LLC (DHS) sued Vascular Health Sciences, LLC (VHS) in the United ...
Breaking Medicine News(10 mins):Health News:Top Mesothelioma Researchers Highlight Targeted Therapies in New Report, According to Surviving Mesothelioma 2Health News:TheBeautyPlace.com Discounts Shipping on Select Brands 2Health News:FCPX Effects Developer, Pixel Film Studios, Releases ProDrop Particles. 2Health News:NEW APPROACH for Treatment of Recurrent Hamstring Strains and Hamstring Tendinosis is Available for the First Time in NYC 2Health News:NEW APPROACH for Treatment of Recurrent Hamstring Strains and Hamstring Tendinosis is Available for the First Time in NYC 3
... A study in the New England Journal of Medicine ... of lung cancer are responding positively to a treatment that ... shows 57 percent of patients with ALK-positive advanced non-small cell ... crizotinib, an investigational anaplastic lymphoma kinase (ALK) inhibitor. In some ...
... Beta cells, which make insulin in the human body, do ... may be closer to better treating diabetes. Type 1 ... auto-immunity while type 2 is due to a relative insufficiency ... remained an open issue, and is critically important for designing ...
... -- The rate of new cases of end-stage kidney disease ... between 1996 and 2007, a new study has found. ... end-stage renal disease (ESRD), that was linked to diabetes declined ... time. The declining rates occurred in all regions and in ...
... the immune system and nervous system turn Neuroimmunology into ... Between October 26th and 30th takes place in Sitges ... the International Society of Neuroimmunology. This event highlights the ... to new technologies, but also highlights the long road ...
... Commonwealth University Massey Cancer Center recently was awarded ... Tobacco Indemnification and Community Revitalization Commission (Tobacco Commission) ... involvement and to grow its state-of-the-art clinical research ... is already in place in communities across Virginia, ...
... (HealthDay News) -- Two-thirds of preschoolers in the United ... hours per day of screen time from television, computers, ... of Pediatrics, a new study has found. Researchers ... Washington looked at the daily screen time of nearly ...
Cached Medicine News:Health News:People with specific kind of lung cancer respond to new targeted treatment 2Health News:People with specific kind of lung cancer respond to new targeted treatment 3Health News:Insulin-creating cell research may lead to better diabetes treatment 2Health News:Drop Seen in Rate of End-Stage Kidney Disease in Diabetics 2Health News:Multiple sclerosis will become a controlled disease like AIDS 2Health News:VCU Massey Cancer Center awarded $2.4 million grant from Virginia Tobacco Commission 2Health News:U.S. Preschoolers Getting Too Much Screen Time: Study 2
... A stethoscope adapter for users of ... acrylic shell type., ,Impressions of ... ,Westone custom products for the ear ... of hearing healthcare providers. These providers ...
Advanced architecture. Small, lightweight and compact. Easy to use....
... bronchoscopy: The HF-compatible V series from Pentax, ... bronchoscopes are measured., ,The HF-compatible series ... FB-19TV, FB-18V and FB-15V models along with ... FB-8V, offer much better image quality thanks ...
... benefits of fibre bronchoscopy: The HF-compatible V ... all other fibre bronchoscopes are measured., ... PENTAX, including the FB-19TV, FB-18V and FB-15V ... and the pediatric FB-8V, offer much better ...
Medicine Products: